Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells (Q45861979)

17 December 2017

title

Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells (English)

1 reference

17 December 2017

1 reference

Yoshimitsu M

1

1 reference

17 December 2017

Higuchi K

2

1 reference

17 December 2017

Ramsubir S

3

1 reference

17 December 2017

Nonaka T

4

1 reference

17 December 2017

Rasaiah VI

5

1 reference

17 December 2017

Siatskas C

6

1 reference

17 December 2017

Liang SB

7

1 reference

17 December 2017

Murray GJ

8

1 reference

17 December 2017

Brady RO

9

1 reference

17 December 2017

Medin JA

10

1 reference

17 December 2017

publication date

24 August 2006

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

page(s)

256-265

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302839

exact match

0 references

cites work

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Cord-blood transplants from unrelated donors in patients with Hurler's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and S

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Preselective gene therapy for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Lentiviruses as gene transfer agents for delivery to non-dividing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

alpha-Galactosidase A deficient mice: a model of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

HIV-1 integration in the human genome favors active genes and local hotspots

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Transcription start regions in the human genome are favored targets for MLV integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

Enzymatic Defect in Fabry's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

7 January 2021

An atypical variant of Fabry's disease in men with left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

7 January 2021

Transduction of Human CD34+CD38- Bone Marrow and Cord Blood-Derived SCID-Repopulating Cells with Third-Generation Lentiviral Vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

7 January 2021

Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

7 January 2021

Murine leukemia induced by retroviral gene marking

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

7 January 2021

AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302839

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302839

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017